Paris, France
Paris, France

Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. The company is based in Paris. Wikipedia.


Time filter

Source Type

The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X-Rays, -Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same.


Grant
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: NMP-09-2014 | Award Amount: 2.00M | Year: 2015

ENATRANS main objective is to network and support SMEs in translation of nanomedicine in Europe by providing a one-stop-shop service to interact and share information, experience and advice with up-to-date information and interactive tools, but also enabling personal contacts. To be successful SMEs need to understand the requirements of the complex ecosystem made up of regulatory and reimbursement agencies, as well as the requirements of large industrial companies and clinical needs. ENATRANS will gather and provide information about approval processes, regulatory authorities and agencies, clinical and market data, and specific nanomedicine value chain analysis, relevant SME support projects and organisations. ENATRANS will convert this critical information in dedicated learning programs and tools dedicated to translation of nanomedicine. ENATRANS aims at implementing the concept of a Translation Advisory Board (TAB) as central element of the ETPN White Paper. A TAB will be set-up with senior experienced translation experts to guide R&D teams (in SMEs and research institutes) along the translation process to successfully make it to clinical trials and later to the market. Promising projects identified and supported by the TAB need access to clinical centers for first studies in patients, which are able to handle the specificity of new nanotechnology based therapeutics. In addition, financial resources are needed to go pass the regulatory and scale-up processes, which often require funding from investors and/or large companies. ENATRANS will build bridges to clinical trial centers, investors and large companies. Promising projects need guidance to successfully master privileged contacts with the medical, the business or the investment community. ENATRANS will deliver special coaching sessions prior to showcasing of promising projects. Partners in ENATRANS are VDI/VDE-IT, Nanobiotix, CEA, bioanalytik-muenster, Tel Aviv University, Fondazione Don Gnocchi, TecMinho.


Patent
Nanobiotix, French National Center for Scientific Research and University of Bordeaux Segalen | Date: 2015-10-19

The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.


Patent
Nanobiotix | Date: 2014-05-30

The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest in a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered in said subject between more than 5 minutes and about 72 hours one from each other.


Patent
Nanobiotix | Date: 2014-06-19

The present invention relates to compositions and methods for use in medical diagnosis and patients monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein i) the nanoparticle and/or nanoparticles of the aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s^(1 )of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pas and about 1000 Pas when measured between 20 C. and 37 C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using X-ray imaging equipment.


Patent
Nanobiotix | Date: 2014-06-19

The present invention relates to compositions and methods for use in medical diagnostic and patient monitoring, typically in the context of therapy, in particular in the context of oncology to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticles aggregates, wherein i) the density of each nanoparticle and of each nanoparticle aggregate is of at least 7 g/cm^(3), the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s^(1 )of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pas and about 1000 Pas when measured between 20 C. and 37 C.


The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.


The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticles aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticles aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticles aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticles aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.


Patent
Nanobiotix | Date: 2015-05-08

The present invention relates to novel activatable particles which can be used in the health sector. The invention more particularly relates to composite particles which can generate free radicals or heat when excited by X rays, and to the uses thereof in health, particularly human. The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same.


The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticle aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticle aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticle aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticle aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.

Loading Nanobiotix collaborators
Loading Nanobiotix collaborators